NGT: Act Against Pharma Co. For Unsafe Disposal Of Biomed Waste

Chennai : The National Green Tribunal (NGT) has directed Tamil Nadu Pollution Control Board (TNPCB) to act against a Chennai-based pharma company for unsafe disposal of biomedical waste.

Inter Med, which has a tablet manufacturing unit in Porur, had dumped hazardous waste at a private land abutting Alapakkam Main Road. The corporation which spotted this violation collected a fine of ₹5,000 from the firm in August 2021.

But there was no follow-up action by the TNPCB. So, NGT Southern Zone, which was recently hearing a case pertaining to biomedical waste in Chennai, called this ‘unfortunate’ and directed the board to collect compensation from the firm.

During the hearing, GCC claimed that it had installed 50 CCTV cameras at vulnerable locations (of waste dumping) and a team at Ripon Buildings was monitoring the situation round the clock.

The civic body further told the tribunal that violators were booked under various provisions under the Biomedical Waste Management Rules, 2016 and in one such case (reported at Sri Lakshmi Nagar in Valasaravakkam) they had lodged a police complaint.

Besides this, the tribunal has told TNPCB to explore the possibility of tracing the total purchase and disposal of biomedical articles by healthcare units so that there is 100% transparency in the process. The NGT has given four months’ time to the board to submit a report regarding this.

At present, there are 4,240 healthcare facilities within the corporation limit, according to official data. All of them have obtained authorisation from the TNPCB to safely dispose of the biomed waste through agreements executed with two common biomedical waste treatment facilities.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’